


The Data-Driven R&D Autobahn to Cures

*Global leadership in
data, science & access*





Disclaimer

This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

Non-IFRS Measures


This presentation contains references to certain non-IFRS measures including EBITDA and Adjusted EBITDA, each of which are not recognized under International Financial Reporting Standards (“IFRS”). The Company believes that non-IFRS financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance and assists in comparisons with other companies, some of which use similar non-IFRS financial information to supplement their IFRS results. The non-IFRS financial information is presented for supplemental informational purposes only, and should not be considered a substitute for financial information presented in accordance with IFRS, and may be different from similarly titled non-IFRS measures used by other companies. EBITDA and Adjusted EBITDA each have limitations as an analytical tool, respectively, and you should not consider any of these measures either in isolation or as a substitute for other methods of analyzing the results as reported under IFRS. Our management team uses these non-IFRS financial measures to evaluate our profitability and efficiency, to compare operating results to prior periods, and to measure and allocate financial resources internally. However, management does not consider such non-IFRS measures in isolation or as an alternative to measures determined in accordance with IFRS. See appendix to this presentation for a reconciliation of Adjusted EBITDA to the nearest GAAP measure.

Agenda

Unique business strategy and capabilities to improve efficiency

Precision medicine platforms to improve probability of success

Building a strong growth business and a large royalty pool




Unique strategy and capabilities to improve Efficiency & Probabilities of Success

QUANTUM
LEAP



Bringing the industry closer together

Our contribution to the industry



„The goal of Evolution is not one single human, it is mankind.“

Manfred Eigen
1927–2019, Co-founder of Evotec,
Nobel Prize 1967

We design medicines for difficult to treat diseases in **efficient collaborations**

We focus on data driven precision medicine and early disease relevance to **improve Probabilities of Success**

We built the “shared economy” in R&D, designed to result in **a large royalty pool**

Panomics and tech convergence bring up Probability of Success


Current challenges in R&D

Key challenges

R&D model is inefficient	<i>Challenging returns due to “too late and “expensive failure”</i>
“One drug fits all” is outdated	<i>90% of drugs are efficacious only in 50% of patients</i>
New modalities did not solve all problems	<i>9% of Phase I biologics receive approval²⁾</i>
Emerging technologies are still very fragmented	<i>Precision medicine toolkit, OMICS platforms, and AI/ML</i>


Development costs per asset increase

Cost per asset doubled since 2010, in US\$ m



Commercial returns decrease

IRR since 2010^{1,4)}



¹⁾ IRR = Internal Rate of Return

²⁾ <https://pharmaintelligence.informa.com/~ /media/informa-shop-window/pharma/2021/files/reports/2021-clinical-development-success-rates-2011-2020-v17.pdf>

³⁾ excl. Covid-19 vaccines

⁴⁾ Sources: Deloitte – Centre for Health Solutions: Ten years on measuring the return of pharmaceutical innovation 2020; Evaluate Pharma – World Preview 2018 / World Preview 2020

Significant improvements of Probability of Success are possible

How we can improve Probability of Success (PoS) in early R&D (**Examples/simplified**)

Today's use of AI/ML

Target identification


System biology to better understand diseases
e.g. associating existing targets with new diseases

Lead optimisation

In silico classification of targets via computational chemistry e.g. better prioritised drugs accelerated

Trial design


Understanding sub populations via biomarkers
e.g. better patient stratification




Still a highly fragmented industry

Selected AI/ML companies (Industry landscape – Illustrative & highly simplified)

Many players at work to initiate a new “data driven” industry paradigm



Convergence of precision medicine platforms to improve probability of success



Developing precise medicines with panomics & tech convergence

Overview



R&D efficiency platforms

















Precision medicine platforms

Right modality drug design

Just – Evotec Biologics



Data-driven R&D Autobahn to Cures – combining all relevant parts for an integrated, end-to-end approach

 Target ID & validation	 Hit identification	 Lead optimisation	 In vivo Pharmacology
 Chemistry	 Bio Reagents	 Integrated CMC	 DMPK & ADME-Tox
 Biomarker discovery	 Antibody discovery	 In vitro biology	 Sample management
 Integrated pre-clinical development	 Clinical development solution	 Research informatics	 INDIGO

E.SOLVE **E.INVENT-AI**
MOLECULAR DESIGN EXCELLENCE

EVOpanHunter
EVOpanOmics
EVOgnostic
E.iPSC
DRUG DISCOVERY
E.MPD
TRANSLATIONAL MOLECULAR PATIENT DATABASE
ScreenSeq
HIGH-THROUGHPUT TRANSCRIPTOMICS
ScreenPep
HIGH-THROUGHPUT PROTEOMICS
E.SAFETY
TOX AND SAFETY PREDICTION
E.iBETA

EVOgenes
EVOcells
E.RNA
TARGETING RNA SPACE
Antibodies & Bifunctionals
Antisense
Exosomes
Protein degradation
Small molecules

J.DISCOVERY™
MOLECULE DISCOVERY
J.HAL™
AI DESIGNED mAb LIBRARY
J.MD™
MOLECULE DESIGN
JP3®
PROCESS & PRODUCT DESIGN
J.POD®
MANUFACTURING DESIGN

Continued strong partnerships with precision medicine platforms

Most significant alliances signed in H1 2022



R&D efficiency platforms

Precision medicine platforms

Right modality drug design

Just – Evotec Biologics



Data-driven R&D Autobahn to Cures



Ophthalmology; iPSC- and **EVOpanOmics**;
Undisclosed upfront and milestone payments, layered royalties



Neurodegeneration; iPSC and expansion on target protein degradation



Target protein degradation / molecular glues; **EVOpanOmics** & **EVOpanHunter**;
€ 200 m upfront, € 5 bn deal value, tiered royalties



Kidney diseases & diabetes; **E.MPD**; **EVOpanOmics**; Undisclosed upfront payment; Five programmes with milestone payments of up to US\$180 preprogramme, tiered royalties




Protein homeostasis; TargetAlloMod;
€210 m milestone payment per project, tiered royalties

Integrated approach for deeper understanding of diseases

Multi-omics analyses on patient samples combined with iPSC based disease modelling

E.MPD
TRANSLATIONAL MOLECULAR PATIENT SAMPLES DATA

E.iPSC
DRUG DISCOVERY




Protein degradation partnership with BMS becomes strategic

Using *EVOpanOmics* & *EVOpanHunter* – Quantum Leap in 2022




Proteomics approach to targeted protein degradation

Development of novel therapies for a broad range of diseases



E.MPD core component of alliances in CKD

CKD strategic drug discovery deals



From Target identification & validation, via biomarker identification, to patient stratification


iPSC already highly productive, ...”but just the beginning”

Continuous expansion of disease models and programs to result in new collaborations



iPSC alliance in neurodegeneration

iPSC alliance in Ophthalmology



Proof of concept in iPSC drug discovery from target ID to clinical development shown for Neurodegenerative Diseases

Delivering health by expanding & improving cell therapy research

Overview H1 2022



R&D efficiency platforms

Precision medicine platforms

Right modality drug design

Just – Evotec Biologics



Data-driven R&D Autobahn to Cures



- QRBeta 1.0 – First generation cell therapy for Insulin-dependent diabetes
- iPSC-based beta cells combined with Cell Pouch™




- Acquisition of Rigenerand Srl, Medolla, Italy, now operating as Evotec (Modena) Srl
- Evotec Cell Accelerator: cGMP manufacturing as basis for off-the-shelf cell therapies


Transformative iPSC-based disease modelling & cell therapy

Industry leading iPSC platform


Global precision medicine market¹⁾
in US\$ bn



Global cell therapy market²⁾
in US\$ bn




Global induced pluripotent stem cell (iPSC) Market
in US\$ bn



"iPS cells are a powerful tool to cure intractable diseases because they can be made from patients' somatic cells."

Shinya Yamanaka, Nobel prize laureate



Largest and most sophisticated iPSC platform in the industry

>300 patient-derived cell lines across 15+ disease areas

Optimized for **high reproducibility, high throughput and robustness**

First iPSC-derived drug candidate **entered clinical trials in 2021**

EVOcells – Seamlessly integrating discovery, development and cGMP manufacturing










¹⁾ <https://www.gminsights.com/> Feb 2020, Evotec estimates

²⁾ <https://www.grandviewresearch.com/industry-analysis/cell-therapy-market>, Evotec estimates

<https://www.researchandmarkets.com/reports/4805485/induced-pluripotent-stem-cell-ipsc-global>

Building a iPSC-based cell therapy pipeline

Internal off-the-shelf cell therapy programmes


Field	Program / Project	Disease area	Exploratory	Pre-clinical research	Pre-clinical development	IND / Phase 1
Anti-tumour cell therapy	iNK	IO ¹⁾				
	iM	IO				
	$\gamma\delta$ iT	IO				
	$\alpha\beta$ iT	IO				
Regenerative therapy	 E.iBETA Sernova Cell Pouch™	Diabetes				
	iCM	Heart failure				
Immune-modulation	iMSCs, iMSC exosomes	Various				
	iNK, iTreg	Anti-fibrotic, auto-immune				

iPSC-based cell types

- iNK Natural killer cells
- iT $\alpha\beta$ and $\gamma\delta$ T cells
- iM Macrophages
- iBeta Pancreatic islets
- iCM Cardiomyocytes
- iMSC Mesenchymal stromal cells

Shaping the value proposition to meet future demand


Just – Evotec Biologics development update



J.POD® Toulouse (France) EU¹⁾: construction work about to start



Number of partnerships and volume of sales order book already doubled in H1 2022 versus 2021; Latest Alpine Immune Sciences extension to design commercial manufacturing process




Just – Evotec Biologics is still in its build up and initial investment phase, but nevertheless on track to meet AP 2025 goals, despite delayed revenues in 2022


Continuous process outperforming fed batch 20x

Large scale production readiness is imminent

Fully end-to-end continuous process for late-stage products (> 25-day production)



Kg DS¹⁾ per Bioreactor



Programmes of partners with increasing breadth and depth

Just – Evotec Biologics client programmes


Disease area	No. of programmes	Discovery	J.MD Optimization	Pre-clinical development	Clinical manufacturing	Commercial Manufacturing	
Oncology	1	→					
	4	→					
Autoimmune	1	→					
Cardiovascular	2	→					
CNS	1	→					
Infectious diseases	1	→					
	3	→					
	2	→					
Other / undisclosed	ND ¹⁾	→					
	ND	→					

Broad basis for sustained growth

- > 15 partners / 18 programmes
- Well balanced partner structure
 - Large / Mid-sized Pharma
 - Large / Small Biotech
 - Foundations
- Continued emphasis on optimal value mix of
 - Fee for service
 - **EVO**royalty
 - **EVO**equity
- Better access to affordable medicine for all
 >50% of programmes addressing targets set to reach UN SDG 3²⁾

Strong growth of biologics business

New programme wins and sales orderbook value




■ New programmes won

■ Value of new wins

- Number of newly signed programmes in 1H2022 already exceeds number during FY 2021
- New contracts carry significantly higher value than in FY2021
- Progress of projects through development process (discovery, clinical, commercial) and new signings will result in acceleration of business pipeline growth


Building a strong growth business and a large royalty pool



Significant expansion of alliances is basis for long-term success


Attraction, Extension, Retention

Attraction




- Customer base more diversified; revenues have grown significantly

Extension



- Integrated drug discover & development offering yields increasing “share of wallet”
- Faster and better results versus in-house infrastructures

Structural Retention ≥90%



- Solid customer retention rates
- Strong basis for double-digit growth

The growing iceberg of product opportunities

>220 projects including EVOequity and BRIDGEs: ~180 in partnerships, >40 internal R&D

		Neuroscience & Pain				Oncology				Metabolic Diseases			Inflammation & Immunology ¹⁾			Virology		Anti-bacterial		Global Health			
Clinical	Ph3	Insomnia																ND					
	Ph2	DNP				Breast Cancer				Carrick													
	Ph1	Pain				A2A				Carrick			Endo										
ND		ND		ND		Exscientia		EVT801		Carrick		P2X7	Endo	Topas			CHIK-V						
Preclinical					Aeovian				Exscientia		EVT		ND	Fibrocor	Topas	HBV							
					Exscientia		ND		ND	Encaps iB		Topas	Topas	Exscientia	COVID-19		Noso-502	Forge					
Discovery	LO	ND				Facio		IO	ND	ND	Autobahn				Eternygen	Exscientia	LAB150						
		ND		ND		Argobio		ND	ND	EVT	Immunitas		EVT		ND	Topas	LAB282	ND	Malaria				
		ND		EVT		EVT		LAB282		ND	LDD	EVT	Exscientia	Breakpoint	ND	EVT	LAB282	Celmatrix	ND	ND			
	H2L							EVT	EVT			Autobahn	DarkBlue	EVT	EVT	ND	ND	ND					
		ND						EVT	EVT			Breakpoint	LAB282	ND	EVT	ND			Blacksmith	ND			
		ND		ND		EVT		LAB282		EVT	EVT	Carrick	Blacksmith	Danube Labs	EVT	EVT	EVT	ND	ND	Fibrocor	LAB282	Forge	
	AD/Scr.	ND				Autobahn		ND	EVT	EVT			ND	ND			Celmatrix	ND					
		ND		ND		Cajal Neuro		ND	EVT	EVT	Immunitas				ND	ND			CureXsys	ND			
		ND		ND		EVT		Facio		ND	EVT	EVT	Quantro	BELAB1407	ND	ND	EVT	CureXsys	ND	ND			
		ND		ND		EVT		Exscientia		ND	EVT	EVT	Ananke	BELAB2122	ND	EVT	EVT	ND	Exscientia	ND	ND		
		ND		ND		EVT		CureXsys		LAB282	ND	ND	EVT	Exscientia	LAB150	ND	EVT	LAB150	ND	LAB150	ND	Exscientia	Forge
		ND		ND		EVT		EVT		LAB150	ND	ND	EVT	OxVax	Argobio	ND	EVT	ND	EVT	LAB282	ND	LAB282	Exscientia

■ Partnered Pipeline
 ■ Unpartnered Pipeline
 ■ Equity Pipeline
 ■ BRIDGEs Pipeline
 ■ Integrated Drug Discovery

“Evotec Inside”

Steady stream of high-value catalysts


Selected pipeline events within next 12 – 24 months

- Phase III & registration (CHN) JingXin in insomnia (EVT201)
- Phase II data with Bayer in DNP (BAY2395840)
- Phase II initiation with Bayer in Gynaecology (BAY2395840)
- Phase I data in Chikungunya virus (EVT894)
- Phase I data with BMS in CNS (EVT8683)
- Phase I data with Kazia in Oncology (EVT801)
- Phase Ib/II initiation of Exscientia in Oncology (EXS21546)
- Phase I initiation in Covid-19 / HBV (EVT075)
- Phase I Initiation with Bayer in Kidney diseases
- Phase I Initiation with Kidney diseases with other partners
- Phase I initiation with BMS in CNS
- Phase I Initiation with BMS in Oncology
- Multiple co-owned equity companies (not outlined here) will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, ...)

	Molecule	Therapeutic Area/Indication	Partner	Discovery	Pre-clinical	Phase I	Phase II	Phase III
Clinical	EVT201	Insomnia (GABA-A)	京新药业					
	Not Disclosed	Infectious Disease (Antibody)	SK bioscience					
	BAY2395840	Diabetic Neuropathic Pain (B1)						
	CT7001	Oncology (CDK7)	Carrick					
	XP-105	Oncology (mTORC1/2)	XYNOMIC					
	EVT401	Immunology & Inflammation (P2X7)	康源集团 CONSEA GROUP					
	BAY2328065	Gynaecology						
	EXS21546	Oncology (various programmes)	Exscientia					
	CNTX 6016	Pain (CB2)	CENTREXION					
	EVT894	Chikungunya (Antibody)	SANOFI					
	Not Disclosed	Neuroscience & Pain	n.a.					
	Not Disclosed	Neuroscience & Pain	n.a.					
	EVT801	Oncology (VEGFR3)	KAZIA					
	EVT8683	Neurodegeneration (eIF2b activator)	Bristol Myers Squibb*					
	TPM203	Pemphigus Vulgaris (ND)	Topas Therapeutics					
CT7001	Oncology (CDK7)	Carrick						
CT7001	Oncology (CDK7)	Carrick						
Pre-clinical	APN411	Oncology – Immunotherapy	SANOFI APEIRON					
	GLPGxxxx	Fibrosis (not disclosed)	galapagos					
	BAYxxxx	Nephrology (not disclosed)						
	QRB001	Metabolic – Diabetes (not disclosed)	QRbeta					
	EVT075	Covid-19 / HBV	n.a.					
	Not disclosed	Various programmes	Bristol Myers Squibb*					
EVTxxxx	CNS, Metabolic, Pain, ...	>10 further programmes						
Discovery	Multiple programmes across nephrology, oncology, immunology among other therapeutic areas							

EVOequity accelerates co-owning strategy

Operational VC model - diversified portfolio with multiple shots on goal



Attractive portfolio with significant upside

At Equity Holding (≥20%) or Significant influence



Minority Shareholdings (<20%)



BRIDGES



On track towards reaching AP 2025 goal

Guidance 2022

	Guidance 2022	YE 2021	Implied growth at midpoint
Group revenues (H1 2022) (at constant fx-rates ¹⁾)	€ 715 – 735 m (€ 690 – 710 m)	€ 618 m	>15%
Unpartnered R&D²⁾	€ 70 – 80 m	€ 58 m	~30%
Adjusted EBITDA³⁾ (at constant fx-rates; H1 2022)	€ 105 – 120 m (€ 85 – 100 m)	€ 107 m	At least stable


Approx. € 300 m investment programme for enabling and supporting growth (e.g. capacity expansion, ...)

Clear strategy in place

Growth and investment strategy overview – Action Plan 2025


Targeted revenue development

(in € m)




Revenue composition 2020

- EVT Execute
- Just – Evotec Biologics¹⁾
- EVT Innovate



Goal revenue composition

- EVT Execute
- Just – Evotec Biologics¹⁾
- EVT Innovate



- Composition of revenue mix expected to change over time while ALL fields continue to grow
- Shifting to even more favourable revenue mix expected to drive increased profitability
- Just – Evotec Biologics growth driven by use of J.POD[®] manufacturing
- First small royalties from pipeline assets expected in 2025

Setting the pace to accelerate growth along Action Plan 2025

Selected major newsflow 2022



R&D efficiency platforms

- Undisrupted growth of base business, in-line with AP 2025 (**EVOiR&D**) ✓
- New integrated drug discovery & development alliances ✓
- Significant capacity and value chain expansion for all modalities ✓

Precision medicine platforms

- New strategic partnerships and expansions of co-owned alliances ✓
- New clinical trial initiations
- Significant progress of later stage co-owned pipeline (**EVOroyalty**)
- Spin-Offs and investments along Building Blocks of AP 2025 (**EVOequity**)


Just – Evotec Biologics

- Start of production J.POD® Redmond, WA (US)
- Start of construction J.POD® Toulouse, France (EU)¹⁾
- Evaluation of global network of J.PODs® (**EVOaccess**)

Group & ESG

- Undisrupted growth trend versus 2021 in line with AP 2025 ✓
- Growth of unpartnered R&D investments faster than top-line ✓
- Validated science-based targets aligned with 1.5°C goal
- Highly impactful contribution to UN SDG 3²⁾

¹⁾UN Sustainable Development Goal 3: Improve health and well-being with main targets for us on women’s health, fight against infectious diseases and pandemic preparedness

1)  This project benefits from French government funding as part of the Investments for the future Programme (programme d’investissements d’avenir in French) and is also supported economically by the Occitanie Region and Toulouse Métropole.
 2) UN Sustainable Development Goal 3: Improve health and well-being with main targets for us on women’s health, fight against infectious diseases and pandemic preparedness

Looking forward to seeing you in person

Financial calendar 2022

Quarterly Statement Q1 2022	✓	11 May 2022
Virtual Annual General Meeting 2022	✓	22 June 2022
Half-year 2022 Interim Report	✓	11 August 2022
Capital Markets Day in Seattle / Redmond		02 November 2022
Quarterly Statement 9M 2022		09 November 2022



#RESEARCHNEVERSTOPS




On site at Just – Evotec Biologics

In person and virtual


Capital Markets Day on 02 November 2022

Appendix




Action Plans deliver significant value

Action Plans in numbers - “... we are just at the beginning”



Platforms and panomics technologies for more precision and efficiency

Evotec today – 16 Sites and more than 4,500 employees



USA

>500

- Branford
- Princeton
- Redmond, WA
- Seattle
- Watertown



Austria

~40

- Orth an der Donau

Italy

>850

- Verona (Campus Levi-Montalcini)
- Modena

Germany

>1,100

- Hamburg (HQ) & Goettingen (Manfred Eigen Campus)
- Cologne
- Munich

UK


>950

- Abingdon (Dorothy Crowfoot Hodgkin Campus)
- Alderley Park

France

>950

- Lyon
- Toulouse (Campus Curie)




Great talent pool

Overview Employees – more than 4,500

Interdisciplinary


- Biochemists
- Medicinal chemists
- Molecular biologists
- Cell biologists
- Toxicologists
- Data scientists
- Process/Analytical chemists
- Clinicians
- mAb process engineers

International¹⁾



Highly qualified

76% with at least one academic qualification




Diverse and experienced

- 84 nationalities
- >30% PhDs
- Average age: 38.5 years
- 54% women
- > 36% with more than five years at Evotec


Our purpose is to go VERY long as ONE – *#researchneverstops*

Sustainable thinking is holistic and ensures long-term success



Strong team and shareholders supporting sustainable growth

Management & shareholder structure¹⁾



Number of shares: 177.0 m

Listings: Frankfurt Stock Exchange (MDAX, TecDAX), Ticker: EVT
NASDAQ Global Select Market (ADS), Ticker: EVO

52 week high/low: € 45.47/€ 17.19

Management Board

- **Werner Lanthaler (CEO)**
Long-time experience in Pharma & biotech
- **Cord Dohrmann (CSO)**
Long-time experience in drug discovery
- **Matthias Evers (CBO)**
Long-time experience in business development, technology and strategy
- **Craig Johnstone (COO)**
Strong drug discovery and commercial track record
- **Enno Spillner (CFO)**
Long-time experience in finance & biotech

Supervisory Board

- **Iris Löw-Friedrich**
UCB
- **Camilla Macapili Languille**
Mubadala Investment Co.
- **Mario Polywka**
Ex-Evotec
- **Roland Sackers**
QIAGEN
- **Elaine Sullivan**
Ex-Lilly
- **Constanze Ulmer-Eilfort**
PSP Munich

Your contact:

Volker Braun
Global Head of Investor Relations & ESG

+49.(0).40.560 81-775
+49.(0).151 1940 5058 (m)
volker.braun@evotec.com

